, Tracking Stock Market Picks
Enter Symbol:
Aptose Biosciences Inc. (APTO) [hlAlert]

down 35.94 %

Aptose Biosciences Inc. (LRP) rated Outperform with price target $17 by Oppenheimer

Posted on: Tuesday,  Dec 9, 2014  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Aptose Biosciences Inc. (NASDAQ: APTO) on 12/09/2014, when the stock price was $7.40. Since
then, Aptose Biosciences Inc. has lost 35.95% as of 11/20/2015's recent price of $4.74.
If you would have followed this Oppenheimer's recommendation on APTO, you would have lost 35.94% of your investment in 346 days.

Lorus Therapeutics is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in- licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/9/2014 8:25 AM Buy
7.40 17.00
as of 8/27/2015
1 Week down  -16.10 %
1 Month down  -10.56 %
3 Months down  -21.78 %
1 YTD down  -35.94 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy